Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia

Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different groups. Recently, a new class of PCSK9 inhibitors...

全面介紹

書目詳細資料

發表在:	Медицинский совет
Main Authors:	A. A. Shikaleva, M. L. Maximov, N. M. Kiseleva
格式:	Article
語言:	俄语
出版:	Remedium Group LLC 2021-01-01
主題:	proprotein convertase subtilisin/kexin type 9 pcsk9 ldl receptor dyslipidemia statins cholesterol hyperlipidemia
在線閱讀:	https://www.med-sovet.pro/jour/article/view/5961